Science & Services
We are developing high-precision liquid-based diagnostic technology based on "single enzyme activity-based protein profiling (SEAP)," which can evaluate the activity of various enzymes in the blood molecule at single protein level.
Our business focuses on 2 main areas: early disease diagnosis and supp
Mission Vision Value
We will contribute to future growth of healthcare by applying fluorescent enzyme substrates and microdevices.
Creating a world without disease and people living life to the fullest
In a world where disease can be detected at an early stage
An cured with the perfect, effective remedy suitable for each individual
No one is afflicted by disease
To realize such future, we will continue to take up the challenge
We act based on our four values (Trust, Respect, Diversity, and Growth) and aim to be a company that you can trust.
- Do our customers truly trust us?
- Do we respect our team members?
- Do we make the most of the diversity of each member?
- Do we grow the company and ourselves as quickly as possible?
Yu Kagami, Ph.D.
CEO & Co-Founder
Yu Kagami, the co-founder of our company in April 2022, has served as CEO since incorporation. Prior to co-founding our company, Yu was engaged in drug review work at the Pharmaceuticals and Medical Devices Agency (PMDA) and in regulatory affairs, clinical development at Janssen Pharmaceuticals. Yu received a Ph.D. in 2016 at the Graduate School of Pharmaceutical Sciences of the University of Tokyo in research on the development of fluorescent dyes.
Shingo Sakamoto, Ph.D.
CTO & Co-Founder
Shingo Sakamoto, Ph.D., the co-founder of our company in April 2022, has served as CTO since incorporation. Shingo has been developing the single enzyme activity-based protein profiling (SEAP) technology since he began his research at the Faculty of Pharmaceutical Sciences of the University of Tokyo. Shingo received the Grand Prize, HAX Tokyo Award, and Mentor Award in the "Entrepreneurship Development" section of EDGE-NEXT Development of MEXT in 2020.
Shizuka Takagi-Niidome, Ph.D.
Shizuka Takagi-Niidome has served as CSO since June 2022. After receiving a Ph.D in 2012 on biochemical research aimed at elucidating the pathogenic mechanism of Alzheimer's disease at the Graduate School of Pharmaceutical Sciences of the University of Tokyo, Shizuka worked as a Research Fellow at Osaka University, as well as a lecturer at Kyoto Pharmaceutical University. Prior to joining our company, Shizuka was engaged in new drug development and organizational reforms as a leader of the R&D department of a drug discovery venture company. Shizuka was awarded the President’s Award from the University of Tokyo in 2008.
Toru Komatsu, Ph.D.
Toru Komatsu, Ph.D., the co-founder of our company in April 2022, has served as Scientific Advisor since incorporation. Currently, Toru is an associate professor at the Graduate School of Pharmaceutical Sciences of the University of Tokyo after working as a postdoctoral fellow at Johns Hopkins University and Scripps Research Institute in the U.S. He also served as a JST-PRESTO researcher (concurrent position) from 2013 to 2017. Toru specializes in chemical biology and drug discovery chemistry.
Rikiya Watanabe, Ph.D.
Rikiya Watanabe, Ph.D., the co-founder of our company in April 2022, has served as Scientific Advisor since incorporation. After working as an assistant professor and lecturer at the Graduate School of Engineering of the University of Tokyo, and as a JST PRESTO researcher (concurrent position), Rikiya is currently a chief scientist at RIKEN, and an adjunct professor at the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University. Rikiya specializes in single molecule biophysics and bioMEMS.
Tadahaya Mizuno, Ph.D.
Tadahaya Mizuno, Ph.D. is an Assistant Professor in the Department of Molecular Pharmacokinetics at the Graduate School of Pharmaceutical Sciences of the University of Tokyo. He specializes in bioinformatics and chemoinformatics.
Kazufumi Honda, D.D.S., Ph.D.
After serving as Assistant Professor of Oral Surgery at Tokyo Medical University, Postdoctoral Fellow at PMDA, Laboratory Head and Unit Director at the National Cancer Center Research Institute, and Director of the Division of Early Diagnostic Biomarker Development at the same institute, Kazufumi is currently a Graduate Professor at the Department of Bioregulation, Graduate School of Medicine, Nippon Medical School. He specializes in tumor biology and biomarker discovery.
- Company Name
- Cosomil, Inc.
- Company Number
- April 1, 2022
- Yu Kagami, Representative Director
- 215 Entrepreneur Lab, South Research Building, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8485, Japan
- Description of Business
- Early detection of diseases and support for drug development by single molecule imaging of enzyme activity
- 2,250,000 yen
- Number of Employees
- 8(as of Jan 1, 2023)